

In the Claims

Please cancel all claims (1-37) and add the following claims 38-63.

38. A method for the treatment of an IgE-related disease comprising administering to a patient a therapeutically effective amount of an isolated and purified antibody or fragment thereof which specifically binds a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2 or 5;
 - b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1, 3 or 4;
 - c) a polypeptide that is at least 70% identical to the polypeptide of a) or b);
 - d) a biologically active fragment of a) - c) above; and
 - e) a derivative or variant of a) - d).
39. The method of Claim 38 wherein said antibody is a monoclonal antibody or fragment thereof.
40. The method of Claim 38 wherein said antibody is a humanized antibody or fragment thereof.
41. The method of Claim 38 wherein said antibody is a fully human antibody or fragment thereof.
42. The method of Claim 38 wherein said antibody is further comprises human chemical modifications.
43. The method of Claim 38 wherein said antibody is a polyclonal antibody or fragment thereof.
44. The method of Claim 38 wherein said antibody is a chimeric antibody or fragment thereof.
45. The method of Claim 38 wherein said antibody is a CDR-grafted antibody or fragment thereof.
46. The method of Claim 38 wherein said antibody is a bispecific, single chain or hetero-antibody or fragment thereof.
47. The method of Claim 38 wherein said antibody is comprises a variable region fragment.
48. The method of Claim 38 wherein said antibody is comprises an Fab, Fab' of F(ab) fragment.
49. The method of Claim 38 wherein said antibody is comprises an Fc fragment.
50. The method of Claim 38 wherein said antibody is bound to a detectable label.
51. The method of Claim 38 wherein said antibody is produced from a hybridoma.
52. The method of Claim 38 wherein said IgE related disease is Type I allergic disease.

53. The method of Claim 38 wherein said IgE related disease is allergic rhinitis.
54. The method of Claim 38 wherein said IgE related disease is eczema.
55. The method of Claim 38 wherein said IgE related disease is dermatitis.
56. The method of Claim 38 wherein said IgE related disease is pollinosis.
57. The method of Claim 38 wherein said IgE related disease is asthma.
58. A method of modulating IgE levels in a patient comprising administering to said patient a therapeutically effective amount of an isolated and purified antibody or fragment thereof which specifically binds a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2 or 5;
 - b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1, 3 or 4;
 - c) a polypeptide that is at least 70% identical to the polypeptide of a) or b);
 - d) a biologically active fragment of a) – c) above; and
 - e) a derivative or variant of a) - d).
59. The method of Claim 58 wherein the IgE levels in a patient are decreased.
60. The method of Claim 58 wherein the IgE levels in a patient are increased.
61. A method of modulating IgE levels in a patient comprising administering to said patient a therapeutically effective amount of a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2 or 5;
 - b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1, 3 or 4;
 - c) a polypeptide that is at least 70% identical to the polypeptide of a) or b);
 - d) a biologically active fragment of a) – c) above; and
 - e) a derivative or variant of a) - d).
62. The method of Claim 61 wherein the IgE levels in a patient are decreased.
63. The method of Claim 61 wherein the IgE levels in a patient are increased.